Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free WHWK Stock Alerts

Whitehawk Therapeutics (WHWK) Competitors

Whitehawk Therapeutics logo
$4.20 +0.05 (+1.08%)
Closing price 03:59 PM Eastern
Extended Trading
$4.20 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

WHWK vs. CGEM, BIOA, RLMD, IVA, and MGTX

Should you be buying Whitehawk Therapeutics stock or one of its competitors? The main competitors of Whitehawk Therapeutics include Cullinan Therapeutics (CGEM), BioAge Labs (BIOA), Relmada Therapeutics (RLMD), Inventiva (IVA), and MeiraGTx (MGTX). These companies are all part of the "pharmaceutical products" industry.

How does Whitehawk Therapeutics compare to Cullinan Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Whitehawk Therapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500.

Cullinan Therapeutics' return on equity of -46.19% beat Whitehawk Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Whitehawk TherapeuticsN/A -62.88% -58.98%
Cullinan Therapeutics N/A -46.19%-43.27%

Whitehawk Therapeutics has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Whitehawk Therapeutics$7.14M29.11-$20.60M$0.478.95
Cullinan TherapeuticsN/AN/A-$219.88M-$3.35N/A

Whitehawk Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 66.47%. Cullinan Therapeutics has a consensus price target of $29.89, suggesting a potential upside of 100.01%. Given Cullinan Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cullinan Therapeutics is more favorable than Whitehawk Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Whitehawk Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Cullinan Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Comparatively, 6.1% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Cullinan Therapeutics had 17 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 19 mentions for Cullinan Therapeutics and 2 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.16 beat Cullinan Therapeutics' score of 0.61 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Whitehawk Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cullinan Therapeutics
4 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Whitehawk Therapeutics and Cullinan Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap manufacturing companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

BioAge Labs has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Whitehawk Therapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Whitehawk Therapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -896.11%. BioAge Labs' return on equity of -27.86% beat Whitehawk Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BioAge Labs-896.11% -27.86% -25.47%
Whitehawk Therapeutics N/A -62.88%-58.98%

Whitehawk Therapeutics has lower revenue, but higher earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAge Labs$9.00M82.32-$80.61M-$2.24N/A
Whitehawk Therapeutics$7.14M29.11-$20.60M$0.478.95

BioAge Labs currently has a consensus price target of $46.25, suggesting a potential upside of 177.21%. Whitehawk Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 66.47%. Given BioAge Labs' stronger consensus rating and higher probable upside, equities analysts clearly believe BioAge Labs is more favorable than Whitehawk Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioAge Labs
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Whitehawk Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

52.1% of Whitehawk Therapeutics shares are held by institutional investors. 20.8% of BioAge Labs shares are held by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, BioAge Labs and BioAge Labs both had 2 articles in the media. Whitehawk Therapeutics' average media sentiment score of 1.16 beat BioAge Labs' score of 0.51 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioAge Labs
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Whitehawk Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

BioAge Labs and Whitehawk Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Relmada Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Whitehawk Therapeutics currently has a consensus price target of $7.00, suggesting a potential upside of 66.47%. Relmada Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 63.31%. Given Whitehawk Therapeutics' higher possible upside, equities research analysts clearly believe Whitehawk Therapeutics is more favorable than Relmada Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Whitehawk Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Relmada Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71

Whitehawk Therapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.

In the previous week, Whitehawk Therapeutics and Whitehawk Therapeutics both had 2 articles in the media. Whitehawk Therapeutics' average media sentiment score of 1.16 beat Relmada Therapeutics' score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Whitehawk Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Relmada Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Whitehawk Therapeutics' return on equity of -62.88% beat Relmada Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Whitehawk TherapeuticsN/A -62.88% -58.98%
Relmada Therapeutics N/A -170.83%-145.58%

Whitehawk Therapeutics has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Whitehawk Therapeutics$7.14M29.11-$20.60M$0.478.95
Relmada TherapeuticsN/AN/A-$57.38M-$1.45N/A

Summary

Whitehawk Therapeutics beats Relmada Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Inventiva?

Whitehawk Therapeutics (NASDAQ:WHWK) and Inventiva (NASDAQ:IVA) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Whitehawk Therapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

In the previous week, Whitehawk Therapeutics and Whitehawk Therapeutics both had 2 articles in the media. Whitehawk Therapeutics' average media sentiment score of 1.16 beat Inventiva's score of 0.69 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Whitehawk Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Inventiva
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Whitehawk Therapeutics currently has a consensus price target of $7.00, suggesting a potential upside of 66.47%. Inventiva has a consensus price target of $16.56, suggesting a potential upside of 206.02%. Given Inventiva's stronger consensus rating and higher possible upside, analysts plainly believe Inventiva is more favorable than Whitehawk Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Whitehawk Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Inventiva
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
3 Strong Buy rating(s)
3.10

52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by insiders. Comparatively, 32.0% of Inventiva shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Inventiva's return on equity of 0.00% beat Whitehawk Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Whitehawk TherapeuticsN/A -62.88% -58.98%
Inventiva N/A N/A N/A

Whitehawk Therapeutics has higher revenue and earnings than Inventiva.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Whitehawk Therapeutics$7.14M29.11-$20.60M$0.478.95
Inventiva$5.07M155.74-$400.67MN/AN/A

Summary

Inventiva beats Whitehawk Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to MeiraGTx?

Whitehawk Therapeutics (NASDAQ:WHWK) and MeiraGTx (NASDAQ:MGTX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Whitehawk Therapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500.

Whitehawk Therapeutics currently has a consensus price target of $7.00, suggesting a potential upside of 66.47%. MeiraGTx has a consensus price target of $25.67, suggesting a potential upside of 163.52%. Given MeiraGTx's stronger consensus rating and higher possible upside, analysts plainly believe MeiraGTx is more favorable than Whitehawk Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Whitehawk Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
MeiraGTx
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75

Whitehawk Therapeutics has higher earnings, but lower revenue than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Whitehawk Therapeutics$7.14M29.11-$20.60M$0.478.95
MeiraGTx$81.39M9.75-$114.20M-$1.42N/A

Whitehawk Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -140.31%. Whitehawk Therapeutics' return on equity of -62.88% beat MeiraGTx's return on equity.

Company Net Margins Return on Equity Return on Assets
Whitehawk TherapeuticsN/A -62.88% -58.98%
MeiraGTx -140.31%-1,065.47%-53.33%

52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by insiders. Comparatively, 7.5% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Whitehawk Therapeutics and Whitehawk Therapeutics both had 2 articles in the media. Whitehawk Therapeutics' average media sentiment score of 1.16 beat MeiraGTx's score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Whitehawk Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MeiraGTx
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Whitehawk Therapeutics and MeiraGTx tied by winning 8 of the 16 factors compared between the two stocks.

Get Whitehawk Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for WHWK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WHWK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

WHWK vs. The Competition

Export
MetricWhitehawk TherapeuticsPharmaceutical Preparations IndustryManufacturing SectorNASDAQ Exchange
Market Cap$207.85M$892.30M$4.21B$11.87B
Dividend YieldN/A4.84%5.61%5.21%
P/E Ratio8.951.7223.4028.47
Price / Sales29.11120.12188.2260.92
Price / CashN/A20.0752.8236.52
Price / Book1.467.6038.446.67
Net Income-$20.60M-$4.80M$114.66M$332.53M
7 Day Performance1.82%0.09%1.34%2.03%
1 Month Performance19.80%5.64%5.68%9.23%
1 Year PerformanceN/A30.92%18.76%39.62%

Whitehawk Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
WHWK
Whitehawk Therapeutics
4.1862 of 5 stars		$4.21
+1.1%		$7.00
+66.5%		N/A$207.85M$7.14M8.9521
CGEM
Cullinan Therapeutics
3.3525 of 5 stars		$12.95
-6.4%		$29.56
+128.2%		N/A$783.81MN/AN/A30
BIOA
BioAge Labs
2.8429 of 5 stars		$17.24
-6.1%		$46.25
+168.3%		N/A$765.11M$9.00MN/AN/A
RLMD
Relmada Therapeutics
1.42 of 5 stars		$7.25
+2.7%		$12.00
+65.5%		N/A$760.44MN/AN/A10
IVA
Inventiva
3.0369 of 5 stars		$5.21
-0.8%		$16.56
+217.8%		N/A$760.41M$4.48MN/A100

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:WHWK) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel